Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19483410 | 0.84 | CPB2 (0.44) | CPB2CA2CA1GSRRNPEP | |
| SCHEMBL19483409 | 0.84 | CPB2 (0.44) | CPB2CA2CA1GSRRNPEP | |
| SCHEMBL18543797 | 0.83 | CA2 (0.54) | CA2CA1MAPK1 | |
| SCHEMBL19483416 | 0.82 | CPB2 (0.47) | CPB2GSRRNPEPGNAI3GNAO1 | |
| SCHEMBL19483403 | 0.82 | CPB2 (0.47) | CPB2GSRRNPEPGNAI3GNAO1 | |
| SCHEMBL10001196 | 0.81 | CA2 (0.61) | CA2CA1MAPK1 | |
| SCHEMBL1705447 | 0.80 | GSR (0.41) | CPB2CA2CA1GSRRNPEP | |
| SCHEMBL19710550 | 0.79 | CA2 (0.69) | CPB2CA2CA1GSRMAPK1 | |
| SCHEMBL12298621 | 0.79 | CPB2 (0.49) | CPB2CA2CA1GSRMAPK1 | |
| SCHEMBL7559158 | 0.79 | CA2 (0.69) | CPB2CA2CA1GSRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | CPB2 1640/4885CA2 4015/4885CA1 3499/4885 |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | PLOD3, COL1A1, THPO | CPB2 1640/4885CA2 4015/4885CA1 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.